443 filings
Page 5 of 23
6-K
CLLS
Cellectis
29 Dec 22
Current report (foreign)
4:42pm
6-K
CLLS
Cellectis
28 Dec 22
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
4:37pm
6-K
CLLS
Cellectis
22 Dec 22
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
4:31pm
6-K
CLLS
Cellectis
13 Dec 22
Current report (foreign)
8:19am
6-K
CLLS
Cellectis
1 Dec 22
Current report (foreign)
5:07pm
6-K
CLLS
Cellectis
10 Nov 22
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
9:24am
6-K
CLLS
Cellectis
10 Nov 22
Current report (foreign)
8:49am
6-K
CLLS
Cellectis
3 Nov 22
Current report (foreign)
5:09pm
6-K
CLLS
Cellectis
3 Nov 22
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
4:43pm
6-K
CLLS
Cellectis
3 Nov 22
Current report (foreign)
4:14pm
SC 13D/A
CLLS
Cellectis
1 Nov 22
Calyxt / Cellectis ownership change
4:30pm
6-K
CLLS
Cellectis
27 Oct 22
Cellectis to Report Third Quarter 2022 Financial Results
4:43pm
6-K
CLLS
Cellectis
11 Oct 22
Current report (foreign)
4:30pm
S-8
CLLS
Cellectis
6 Oct 22
Registration of securities for employees
4:16pm
6-K
CLLS
Cellectis
5 Oct 22
Current report (foreign)
4:30pm
6-K
CLLS
Cellectis
28 Sep 22
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
4:30pm
6-K
CLLS
Cellectis
22 Sep 22
Current report (foreign)
4:32pm
6-K
CLLS
Cellectis
1 Sep 22
Cellectis Announces Participation in Four Upcoming Investor Conferences in September
4:56pm
6-K/A
CLLS
Cellectis
31 Aug 22
Current report (foreign) (amended)
4:22pm
6-K
CLLS
Cellectis
29 Aug 22
Current report (foreign)
8:03am